Zinc picolinate

Zinc picolinate 是一种口服有效的锌补充剂,可降低 Hsp70 表达、抑制氧化性 DNA 损伤、提高血清 ALP 活性、降低 MDA 浓度、提高 SOD 水平并提升血清、全身及血浆中的锌浓度,且不改变虹鳟体内的铜、锰含量,对 Sprague Dawley 大鼠中 Acetic acid (MS-H89626) 诱导的实验性结肠炎具有保护作用,可缩小子宫肌瘤体积、减轻结肠氧化损伤、缓解结肠炎症并增强肠屏障完整性,因此可用于子宫肌瘤、溃疡性结肠炎及慢性阻塞性肺疾病的相关研究。
产品编号: MS-C23280 CAS No.: 17949-65-4 分子式: C12H8N2O4Zn 分子量: 309.58
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5g
询价
3-5 天
10g
询价
3-5 天
25g
询价
3-5 天
50g
询价
3-5 天
100g
询价
3-5 天
500g
询价
3-5 天
> 100g
询价
询价

产品描述

Zinc picolinate 是一种口服有效的锌补充剂,可降低 Hsp70 表达、抑制氧化性 DNA 损伤、提高血清 ALP 活性、降低 MDA 浓度、提高 SOD 水平并提升血清、全身及血浆中的锌浓度,且不改变虹鳟体内的铜、锰含量,对 Sprague Dawley 大鼠中 Acetic acid (MS-H89626) 诱导的实验性结肠炎具有保护作用,可缩小子宫肌瘤体积、减轻结肠氧化损伤、缓解结肠炎症并增强肠屏障完整性,因此可用于子宫肌瘤、溃疡性结肠炎及慢性阻塞性肺疾病的相关研究。

生物实验数据

生物活性 Zinc picolinate is an orally effective zinc supplement that reduces Hsp70 expression, inhibits oxidative DNA damage, increases serum ALP activity, decreases MDA concentration, elevates SOD levels, and raises zinc concentrations in serum, the whole body, and plasma, without altering copper or manganese content in rainbow trout; it exerts protective effects against Acetic acid (MS-H89626)-induced experimental colitis in Sprague Dawley rats, reduces uterine fibroid volume, alleviates colonic oxidative damage, mitigates colonic inflammation, and enhances intestinal barrier integrity, and can therefore be used in research related to uterine fibroids, ulcerative colitis, and chronic obstructive pulmonary disease.
IC50 & Target

HSP70

 

体内研究
(In Vivo)

Zinc picolinate (日粮添加 30-60 mg zinc/kg;口服;每日自由摄取;持续 350 天) 可显著减小日本鹌鹑自发性输卵管平滑肌瘤的体积,降低全身氧化应激标志物水平,并下调肌瘤组织中 Hsp70 的表达。
Zinc picolinate (日粮中锌含量 30-60 mg Zn/kg;口服;每日 2 次;持续 55 天) 可呈线性降低虹鳟的氧化应激 (以 MDA 浓度为检测指标),并提高其血清 ALP 活性和组织锌水平,且不会影响其生长、采食量、饲料效率或铜/锰浓度。
Zinc picolinate (6 mg/kg;腹腔注射;每日一次;连续 10 天) 可通过减轻氧化应激、抑制局部及全身炎症、增强肠屏障完整性并改善组织病理学结果,对雄性 Sprague Dawley 大鼠的乙酸诱导溃疡性结肠炎起到保护作用,同时可显著降低结肠 TNF-α 水平及组织病理学评分。
Zinc picolinate (6 mg/kg;腹腔注射;每日一次;连续 10 天) 可调节健康雄性 Sprague Dawley 大鼠结肠细胞因子和紧密连接蛋白的表达,显著升高结肠 TNF-α 水平,降低结肠 IL-6、occludin-1 和 claudin-1 水平,且不改变宏观或组织病理学结果。

Animal Model: Coturnix coturnix japonica (6-month-old)
Dosage: 30 mg/kg of diet; 60 mg/kg of diet
Administration: p.o.; ad libitum daily; 350 days
Result: Showed no significant difference in tumor incidence between treatment and control groups (10% for 30 mg/kg group, 14% for 60 mg/kg group, vs. 16% control).
Reduced average tumor diameters significantly: 2.6 mm for the 30 mg/kg group and 2.9 mm for the 60 mg/kg group, compared to 4.8 mm in controls (P =.01).
Reduced serum oxidative stress markers significantly in a linear dose-dependent manner (P =.01): serum MDA was 1.34 μmol/L (30 mg/kg) and 0.93 μmol/L (60 mg/kg) vs. 1.95 μmol/L control; serum 8-isoprostane was 93 pg/mL (30 mg/kg) and 85 pg/mL (60 mg/kg) vs. 108 pg/mL control; serum HAE was 1.21 μmol/L (30 mg/kg) and 0.96 μmol/L (60 mg/kg) vs. 1.55 μmol/L control; serum 8-OHdG was 23.6 ng/mL (30 mg/kg) and 20.1 ng/mL (60 mg/kg) vs. 28.5 ng/mL control.
Decreased Hsp70 expression in fibroid tissue significantly in a dose-dependent manner (P <.05), with densitometric readings showing ~73% of control levels for the 30 mg/kg group and ~39% of control levels for the 60 mg/kg group.
Animal Model: Oncorhynchus mykiss (0+ y-old, initial average weight 50 g)
Dosage: 30 mg Zn/kg of diet; 60 mg Zn/kg of diet
Administration: p.o.; twice daily; 55 days
Result: Decreased serum malondialdehyde (MDA) concentration to 1.12 nmol/mL, liver MDA to 3.30 nmol/mL, and muscle MDA to 2.15 nmol/mL at 30 mg Zn/kg of diet.
Decreased serum MDA concentration to 0.92 nmol/mL, liver MDA to 2.94 nmol/mL, and muscle MDA to 1.63 nmol/mL at 60 mg Zn/kg of diet.
Increased serum alkaline phosphatase (ALP) activity to 115 U/L, serum Zn concentration to 13.8 μg/mL, and whole body Zn concentration to 47.8 μg/g at 30 mg Zn/kg of diet.
Increased serum ALP activity to 138 U/L, serum Zn concentration to 15.6 μg/mL, and whole body Zn concentration to 52.0 μg/g at 60 mg Zn/kg of diet.
Did not significantly alter body weight gain, feed intake, feed efficiency, or serum/whole body Cu and Mn concentrations at either dose compared to unsupplemented controls.
Decreased serum, liver, and muscle MDA concentrations linearly (P=0.001) with increasing zinc picolinate dose.
Increased serum ALP activity (P=0.01), serum Zn (P=0.01), and whole body Zn (P=0.05) linearly with dose.
Animal Model: Sprague Dawley (male, 12-week-old, 250-300 g, acetic acid-induced ulcerative colitis)
Dosage: 6 mg/kg
Administration: i.p.; daily; 10 days
Result: Attenuated ulcer severity and significantly reduced macroscopic damage score (p < 0.01) and stool consistency score (p < 0.05).
Significantly increased serum zinc levels (p < 0.05).
Significantly reduced colon malondialdehyde (MDA) levels (p < 0.05) and increased colon glutathione (GSH) levels (p < 0.01).
Significantly reduced colon myeloperoxidase (MPO) activity (p < 0.01), serum tumor necrosis factor (TNF)-α levels (p < 0.05), serum interleukin (IL)-6 levels (p < 0.01), colon TNF-α levels (p < 0.001), and colon IL-6 levels (p < 0.001).
Significantly increased colon occludin mRNA expression (p < 0.001) and claudin-1 mRNA expression (p < 0.001), and significantly reduced zonula occludens-1 mRNA expression (p < 0.001).
Significantly reduced histopathological score (p < 0.001) and increased PAS-positive surface mucus and goblet cell count.
Animal Model: Sprague Dawley (male, 12-week-old, 250-300 g)
Dosage: 6 mg/kg
Administration: i.p.; daily; 10 days
Result: Showed no significant changes in macroscopic score, stool quality score, colonic edema score, colon MDA levels, colon GSH levels, colon MPO levels, serum TNF-α levels, serum IL-6 levels, or histopathological score compared to saline-treated healthy rats.
Significantly increased colon TNF-α levels (p < 0.05) and significantly reduced colon IL-6 levels (p < 0.01) compared to saline-treated healthy rats.
Significantly reduced colon occludin-1 mRNA expression (p < 0.001) and claudin-1 mRNA expression (p < 0.001) compared to saline-treated healthy rats; no significant change in zonula occludens mRNA expression.
性状 固体
颜色 White to off-white

化学信息

分子量 309.58
分子式 C12H8N2O4Zn
CAS No. 17949-65-4

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础